The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Hologic to Launch Four New Products at the European Congress of Radiology in Vienna

Wednesday, February 22, 2012

Hologic to Launch Four New Products at the European Congress of Radiology in Vienna09:46 EST Wednesday, February 22, 2012C-View synthesized 2D mammography images for a breast tomosynthesis system, 3D calcification computer-aided detection, specimen radiography system, and next-generation mini C-arm system are some of the new products on displayBEDFORD, Mass., Feb. 22, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will launch four ready-to-market technologies at the European Congress of Radiology (ECR), the annual meeting of the European Society of Radiology in Vienna, Austria, March 1-5. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/hologic/50098/(Photo: http://photos.prnewswire.com/prnh/20120222/MM55988) A prominent feature in the Hologic exhibit is the Selenia Dimensions breast tomosynthesis system, approved for sale in the U.S. in February 2011 and available since 2008 in Europe and other countries recognizing the CE mark. The Hologic Selenia Dimensions tomosynthesis system directly addresses the primary limitations of conventional 2D mammography - the superimposition of normal breast tissue. Breast cancer screening with tomosynthesis has a higher cancer detection rate than conventional 2D mammography and has been demonstrated to significantly reduce recall rates.[i] Shown for the first time at ECR are two new commercial products designed specifically for the Selenia Dimensions system: C-View synthesized 2D images and ImageChecker 3D Calc computer-aided detection.The C-View image reconstruction algorithm creates synthesized 2D images from Selenia Dimensions tomosynthesis datasets, eliminating the need for 2D screening exposures, thereby reducing both compression time and dose. [ii]ImageChecker 3D Calc computer-aided detection uses sophisticated algorithms to search tomosynthesis data sets for microcalcifications potentially associated with breast cancer.Shown for the first time in Europe is the Hologic Trident specimen radiography system. The Trident system is a cost-effective workflow solution to address surgical specimen and core biopsy imaging needs.Shown as a work-in-progress is Hologic's new Fluoroscan InSight- FD mini C-arm system, the next-generation in mini C-arm imaging. The new system is designed to deliver greater arch depth, flexibility and faster acquisition times than the current system.Hologic is sponsoring an ECR Satellite Symposium on Saturday, March 3 from 14.00 to 15.30 in the Austria Center Vienna, Room C. Three distinguished speakers will highlight their experience using breast tomosynthesis in screening and diagnosis, the use of C-View images as a substitute for conventional 2D digital mammography images in tomosynthesis screening, and the potential value of contrast-enhanced mammography in breast cancer detection.Per SkaaneProfessor Dr. Med.Oslo University Hospital Ullevaal, Oslo, NorwayThe Oslo Clinical Tomosynthesis Screening ExperienceDr. Stefano CiattoDivision U.O. Senologia Clinica e Screening Mammografico,Dipartimento di Radiodiagnostica Organization, Trento, ItalyThe Italian Clinical Tomosynthesis ExperienceDr. John LewinDiversified Radiology of Colorado, P.CRose Medical Center, Denver, ColoradoThe Value of Contrast-Enhanced Mammography in Breast Cancer Detection No reservations are required.Hologic is also sponsoring five tomosynthesis workshops at ECR. Each two-hour session, led by an experienced radiologist, will combine a lecture with hands-on tomosynthesis case review. C-View patient images will be shown and discussed in the workshops. Contact Hologic for registration information.  About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.Hologic, C-View, Dimensions, Fluoroscan, ImageChecker, InSight, Selenia and Trident and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Forward Looking Statement Disclaimer This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.Contact:Olga Karagiannis Jim CulleySr. Specialist, Global Publicity & Advertising Director, MarketingHologic, Inc. Hologic, Inc.olga.karagiannis@hologic.com jim.culley@hologic.comTel: +1 781 761 7069 Tel: +1 302 528 1312 [i] FDA PMA submission P080003 and Skaane P, Gullien R, Eben EB, et. al. Reading time of FFDM and tomosynthesis in a population-based screening program. Radiological Society of North America annual meeting. Chicago, Il, 2011. [ii] C-View, the 2D image reconstruction algorithm, and ImageChecker 3D Calc computer-aided detection are CE Marked and meet the legal requirements for selling the product throughout the European Economic Area and in other countries recognizing the CE Mark. These products are not available in the United States.  SOURCE Hologic, Inc.